# US 2012/0251568 A1 · Recombinant influenza viruses and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251568 A1
- Document ID: US20120251568A1
- Status: Published application
- Kind: A1
- Application number: 13/387,293
- Filed: 2010-07-27
- Published: 2012-10-04
- Earliest claimed: 2009-07-27
- Assignees: Icahn School of Medicine at Mount Sinai
- Inventors: Adolfo Garcia-Sastre; Peter Palese; Balaji Manicassamy
- Web page: https://patentgrep.com/patent/US20120251568A1

## CPC

- C12N 15/86: Viral vectors
- A61P 31/16: for influenza or rhinoviruses
- A61P 37/04: Immunostimulants
- C07K 14/005: from viruses
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C07K 2319/50: containing protease site
- C07K 2319/60: containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
- C12N 2760/16121: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2760/16122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/16143: viral genome or elements thereof as genetic vector
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Described herein are modified influenza virus NS gene segments and nucleic acid sequences encoding such modified influenza virus NS gene segments. In certain embodiments, a modified influenza virus NS gene segment described herein comprises an influenza virus NS 1 open reading frame (ORF) lacking a stop codon, a heterologous nucleotide sequence, a 2A autoproteolytic cleavage site or another cleavage site, an NEP ORF, wherein the gene segment has one or more mutations in either the splice acceptor site, splice donor site, or both the splice acceptor and splice donor sites that prevents splicing of mRNA. Also described herein are recombinant influenza viruses comprising a modified influenza virus NS gene segment and the use of such viruses. The recombinant influenza viruses may be use in the prevention and/or treatment of influenza virus disease or as a delivery vector.

## Claims

### Claim 1

A nucleic acid sequence comprising a modified influenza virus NS gene segment or the complement thereof, wherein the modified influenza virus NS gene segment comprises in 3′ to 5′ order:
a. an influenza virus NS1 open reading frame (ORF) lacking a stop codon, a heterologous nucleotide sequence, a cleavage site, and an influenza virus NEP ORF, wherein the modified influenza virus NS gene segment has one or more mutations in either the splice acceptor site, the splice donor site, or both the splice acceptor and splice donor sites that prevents splicing of mRNA;
b. an influenza virus NS1 ORF lacking a stop codon, a linker, a heterologous nucleotide sequence, a cleavage site, and an influenza virus NEP ORF, wherein the modified influenza virus NS gene segment has one or more mutations in either the splice acceptor site, the splice donor site, or both the splice acceptor and splice donor sites that prevents splicing of mRNA;
c. an influenza virus NS1 ORF lacking a stop codon, a cleavage site, a heterologous nucleotide sequence, a cleavage site, and an influenza virus NEP ORF, wherein the modified influenza virus NS gene segment has one or more mutations in either the splice acceptor site, the splice donor site, or both the splice acceptor and splice donor sites that prevents splicing of mRNA; or
d. a heterologous nucleotide sequence, a cleavage site, an influenza virus NS1 ORF, a cleavage site, and an influenza virus NEP ORF, wherein the modified influenza virus NS gene segment has one or more mutations in either the splice acceptor site, the splice donor site, or both the splice acceptor and splice donor sites that prevents splicing of mRNA.

### Claim 2 (depends on 1)

The nucleotide sequence of claim 1, wherein the modified influenza virus comprises an influenza virus NS1 open reading frame (ORF) lacking a stop codon, a heterologous nucleotide sequence, a cleavage site, and an influenza virus NEP ORF.

### Claim 3 (depends on 2)

The nucleic acid sequence of claim 2, wherein the modified influenza virus NS gene segment further comprises a linker between the heterologous nucleotide sequence and the cleavage site.

### Claim 4 (depends on 1)

The nucleic acid sequence of claim 1, wherein the cleavage site is a 2A autoproteolytic cleavage site.

### Claim 5 (depends on 4)

The nucleic acid of claim 4, wherein the 2A autoproteolytic cleavage site is ATNFSLLKQAGDVEENPG⇓P (SEQ ID NO: 20).

### Claim 6 (depends on 1)

The nucleic acid sequence of claim 1, wherein the heterologous nucleotide sequence encodes a viral, fungal, parasite, tumor, or bacterial antigen; a cytokine; or a growth factor.

### Claim 7

(canceled)

### Claim 8 (depends on 1)

The nucleic acid sequence of claim 1, wherein the heterologous nucleotide sequence encodes a detectable substance.

### Claim 9

(canceled)

### Claim 10 (depends on 1)

A DNA encoding the nucleic acid sequence of claim 1.

### Claim 11 (depends on 1)

A substrate comprising the nucleic acid sequence of claim 1.

### Claim 12

(canceled)

### Claim 13 (depends on 1)

A recombinant influenza virus comprising the nucleic acid sequence of claim 1.

### Claim 14 (depends on 13)

The recombinant influenza virus of claim 13 which comprises an attenuating mutation.

### Claim 15 (depends on 13)

A substrate comprising the recombinant influenza virus of claim 13.

### Claim 16 (depends on 13)

A pharmaceutical composition comprising the recombinant influenza virus of claim 13.

### Claim 17 (depends on 13)

An immunogenic composition comprising the recombinant influenza virus of claim 13.

### Claim 18 (depends on 17)

A method for eliciting an immune response against an influenza virus or a heterologous antigen, comprising administering to a subject the immunogenic composition of claim 17.

### Claim 19

(canceled)

### Claim 20 (depends on 16)

A method for delivery a protein to a subject, comprising administering to the subject the pharmaceutical composition of claim 16.

### Claim 21 (depends on 10)

A method for generating a recombinant influenza virus, wherein the method comprises introducing into a host cell the DNA of claim 10, wherein the host cell expresses all other components for generation of the influenza virus; and purifying the influenza virus from the supernatant of the host cell.

### Claim 22 (depends on 13)

A method for propagating a recombinant influenza virus, wherein the method comprises infecting a substrate with the recombinant influenza virus of claim 13 and purifying the virus subsequently from the substrate.

### Claim 23 (depends on 8)

A recombinant influenza virus comprising the nucleic acid sequence of claim 8.

### Claim 24 (depends on 23)

A screening assay to identify a compound that modulates the replication of an influenza virus, comprising:
(a) (i) contacting a compound with a host cell infected with the recombinant influenza virus of claim 23, wherein the recombinant influenza virus expresses the detectable substance, and (ii) measuring the expression or activity of a product encoded by the detectable substance;
(b) (i) infecting a host cell with the recombinant influenza virus of claim 23 in the presence of a compound, wherein the recombinant influenza virus expresses the detectable substance, and (ii) measuring the expression or activity of a product encoded by the detectable substance; or
(c) (i) contacting a compound with a host cell, (ii) infecting the host cell with the recombinant influenza virus of claim 23, wherein the recombinant influenza virus expresses the detectable substance, and (iii) measuring the expression or activity of a product encoded by the detectable substance,
wherein a compound that increases the replication of influenza virus is identified if the level of expression or activity of the product is increased in the host cell contacted with the compound relative to the level of expression or activity of the product in a host cell contacted with a negative control; and wherein a compound that decreases the replication of influenza virus is identified if the level of expression or activity of the product is decreased in the host cell contacted with the compound relative to the level of expression or activity of the product in a host cell contacted with a negative control.
